Início › Câncer de Mama › Wisconsin › Milwaukee
Ensaios clínicos de Câncer de Mama em Milwaukee, WI
23 estudos para Câncer de Mama estão buscando participantes em locais em Milwaukee e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
The Vanguard Study: Testing a New Way to Screen for Cancer
RecrutandoVoluntários saudáveis bem-vindos
- Zablocki Veterans Administration Medical Center, Milwaukee
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
- Aurora Cancer Care-Milwaukee, Milwaukee
- Aurora Saint Luke's Medical Center, Milwaukee
- Aurora Sinai Medical Center, Milwaukee
- e mais 9
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
RecrutandoFase 1
- Research Site, Milwaukee
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
RecrutandoFase 3
- Clinical Trial Site, Milwaukee
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
RecrutandoFase 3
- Medical College of Wisconsin, Milwaukee
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
RecrutandoFase 1/2
- Froedtert & MCW Cancer Center, Milwaukee
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
RecrutandoFase 3
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
RecrutandoFase 2
- Medical College of Wisconsin, Milwaukee
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
RecrutandoFase 3
- Aurora Cancer Care-Milwaukee, Milwaukee
- Aurora Saint Luke's Medical Center, Milwaukee
- Medical College of Wisconsin, Milwaukee
- e mais 8
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RecrutandoFase 1
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial
Recrutando
- Froedtert Hospital, Milwaukee
Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer
Recrutando
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
E-Mindfulness Approaches for Living After Breast Cancer
RecrutandoFase 3
- UW Cancer Center at ProHealth Care, Waukesha · a 17 mi de distância
- ProHealth D N Greenwald Center, Mukwonago · a 25 mi de distância
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
RecrutandoFase 3
- Aurora Cancer Care-Milwaukee, Milwaukee
- Aurora Saint Luke's Medical Center, Milwaukee
- Medical College of Wisconsin, Milwaukee
- e mais 9
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RecrutandoEstudo observacional
- Aurora Cancer Care-Milwaukee, Milwaukee
- Ascension Columbia Saint Mary's Hospital - Milwaukee, Milwaukee
- Aurora Saint Luke's Medical Center, Milwaukee
- e mais 10
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
RecrutandoEstudo observacional
- Medical College of Wisconsin, Milwaukee
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
RecrutandoFase 1
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
RecrutandoEstudo observacional
- Aurora Cancer Care - Wauwatosa, Wauwatosa · a 5 mi de distância
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecrutandoEstudo observacional
- Massive Bio SYNERGY-AI site, Milwaukee
Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer
RecrutandoFase 2
- Froedtert Hospital and the Medical College of Wisconsin, Milwaukee
Individuals on Hormone Therapy Breast Cancer Screening Pilot
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
- Medical College of Wisconsin, Milwaukee
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
RecrutandoEstudo observacional
- Columbia St. Mary's, Milwaukee
Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
Recrutando
- Medical College of Wisconsin, Milwaukee
Ensaios de Câncer de Mama em outras cidades
- New York City, NY136 estudos
- Houston, TX126 estudos
- Boston, MA112 estudos
- Nashville, TN81 estudos
- Los Angeles, CA73 estudos
- Edison, NJ68 estudos
- St. Louis, MO64 estudos
- Queens, NY64 estudos
- Durham, NC64 estudos
- Chicago, IL59 estudos
- Philadelphia, PA56 estudos
- Dallas, TX55 estudos
Outros estudos em Milwaukee
- Câncer (todos os tipos)22 estudos
- Câncer de Pulmão de Não Pequenas Células22 estudos
- Mieloma Múltiplo21 estudos
- Câncer de Pulmão21 estudos
- Câncer de Próstata20 estudos
- Linfoma folicular19 estudos
- Linfoma Não Hodgkin18 estudos
- Câncer de Pâncreas18 estudos
- Leucemia Mieloide Aguda17 estudos
- Câncer de Ovário17 estudos
- Linfoma Difuso de Grandes Células B16 estudos
- Linfoma de Burkitt16 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.